Blossom Pro: Research Briefing #5 – Microdosing for ADHD, PAT in Switzerland, and Repeated Psilocybin Dosing

How can microdosing support people who experience ADHD, and does it work better than conventional medications? The first article explores this across two studies. We then venture into the heart of Europe, where psychedelic-assisted psychotherapy has been legally possible for the last decade (again). Finally, I’ll focus on the flexible repeated dosing in a trial with psilocybin for depression.

Psychedelic Research Recap January 2024

January saw new psychedelic trials on ibogaine for TBI, DMT, and psilocybin for CCHs, alongside re-analyses on psychedelic brain impacts, therapy dynamics in MDMA treatment, and LSD visuals. Studies also probed SSRI-psychedelic interactions, expectancy roles, and heart effects from microdosing.